CITIC Securities: Conch Medicine (09926.HK) Rated as "Buy", Multiple Engines Break Through the Entire Growth Curve

The Securities Times APP learned that Zhongxin Jian Investment released a research report stating that considering the excellent efficacy of the company's innovative drugs and the broad market space, Kangfang Bio (09926.HK) has been given a "buy" rating. In terms of research pipeline, the company has multiple products in the pipeline and indications that are about to be approved for market, while the existing research and development pipeline continues to expand and enrich. With a rich early research pipeline reserve, the company has the ability for long-term sustainable development. In terms of product sales, the market approval for Yida Fang will contribute to the company's product sales, and the steady growth of Kantanni will increase the company's product sales revenue year by year.